Inventor · disambiguated record
Katherine Cygnar
Also filed as: CYGNAR KATHERINE · CYGNAR KATHERINE DIANA
10 granted patents·19 pending applications·53 citations·filing 2013–2025
86Inventor score
Files withREGENERON PHARMA29
Top patents by PatentIndex Score
29 records- 0195US11208458B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2018·Granted Dec 28, 2021·28 cites·20 claims
- 0294US11578135B2Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·8 cites·14 claims
- 0391US11129903B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Sep 28, 2021·8 cites·30 claims
- 0487US11352446B2Methods of making multispecific antigen-binding moleculesREGENERON PHARMA·Filed 2017·Granted Jun 7, 2022·4 cites·26 claims
- 0587US11191844B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Dec 7, 2021·4 cites·31 claims
- 0680US2025171520A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0774US12215138B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2021·Granted Feb 4, 2025·0 cites·24 claims
- 0874US2023345919A1Non-human animals comprising a humanized asgr1 locusREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0973US12297257B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2021·Granted May 13, 2025·0 cites·30 claims
- 1068US12258597B2Methods and compositions for therapeutic protein deliveryREGENERON PHARMA·Filed 2019·Granted Mar 25, 2025·1 cites·23 claims
- 1167US2022267477A1Methods of making multispecific antigen-binding moleculesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1266US2023338477A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1365US12252544B2Anti-CD63 antibodies, conjugates, and uses thereofREGENERON PHARMA·Filed 2019·Granted Mar 18, 2025·0 cites·24 claims
- 1464US2025032642A1Crispr-mediated transgene insertion in neonatal cellsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1563US2025382377A1Anti-cd63 antibodies, conjugates, and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1663US2025188433A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1762US11696572B2Non-human animals comprising a humanized ASGR1 locusREGENERON PHARMA·Filed 2018·Granted Jul 11, 2023·0 cites·25 claims
- 1862US2025049896A1Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiencyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1962US2024052051A1Anti-tfr:payload fusions and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2059US2025194571A1Compositions and methods for defining optimal treatment timeframes in lysosomal diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2158US2025041455A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2256US2023149563A1Compositions and methods for expressing factor ix for hemophilia b therapyREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2354US2013243775A1Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 2452US2025197829A1Methods and compositions for therapeutic protein deliveryREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2551US2023220100A1Bbb-targeted gaa delivered as gene therapy treats cns and muscle in pompe disease model miceREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2648US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2747US2025242018A1Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2845US2025242056A1Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosingREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2943US2019112588A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Katherine Cygnar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →